Brain cancer

…a subtype of glial cells in the brain, can exocytotically release the neurotransmitter glutamate and how this release is regulated. Spatiotemporal characteristic of vesicular fusion that underlie glutamate release in astrocytes will be discussed. He will also present data on a translational project in which this release pathwa

Radiotherapy (RT) is the mainstay of brain cancer treatment due the generation of reactive oxygen species that cause double- and single-stranded DNA breaks. Although tumour cells are more radiosensitive, healthy cells are also subject to radiation damage, and as such therapeutic radiation can induce progressive cognitive decline. We investigated whether radiation-induced cognitive impairments could be prevented with the antioxidant tempol. Male C57BL/6 mice aged 27 weeks were administered either tempol (100mg/kg/day) or 0.9% saline for seven consecutive days via the I.P. route. One day after t

…multiforme (GBM), a highly aggressive brain cancer, with a particular focus on understanding the role of CD9, a transmembrane protein involved in tumor cell invasion, apoptosis, and resistance to chemotherapy. GBM presents major challenges due to its rapid progression and resistance to conventional treatments. Using immunocytochemistry, CD9 is used as a marker to identify distinct cell populations within GBM cultures. Simultaneously, the study investigates CD9 expression patterns by flow cytometry, providing valuable insights into its pot

…development of targeted therapies for brain tumours presented by Dr Ekaterina (Caty) Salimova, Monash Biomedical Imaging Glioblastoma multiforme (GBM) - brain cancer - is aggressive and difficult to treat as systemic therapies are hindered by the blood-brain barrier (BBB). Focused ultrasound (FUS) - a non-invasive technique that can induce targeted temporary disruption of the BBB – is a promising tool to improve GBM treatments. In this webinar, Dr Ekaterina Salimova will discuss the MRI-guided FUS modality at MBI and her research